Valid Ghana · FDA Ghana

OVARIA 30 SACHETES

MYO-INOSITOL

FDA/SD.243-040661 MYO-INOSITOL 4000MG

What it does

Myo-inositol is a natural substance that may help improve insulin sensitivity and support ovarian function.

Commonly used for: polycystic ovary syndrome (PCOS), insulin resistance, ovarian health

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
FDA/SD.243-040661
Registration date
2024-04-29
Expiry date
2028-12-31
Status
Valid
Active ingredient
MYO-INOSITOL
Dosage form
MYO-INOSITOL
Strength
4000MG
Pack size
-
Therapeutic class
-
Manufacturer / MAH
Lamelle Pharmaceuticals
Applicant / LTR
MINARLIFE COMPANY LIMITED
Country of origin
-
Manufacturer location
Loughrea Business & Technology Park, Dublin Rd, Greeneenagh, Loughrea, Co. Galway, Ireland

Source: Food and Drugs Authority · fetched 2026-04-18 08:37:12 · updated 2026-10-20 04:00:09

Disclaimer: This information is sourced from Food and Drugs Authority (Ghana). Always consult a qualified healthcare professional before using any medication.

About this medicine

Myo-inositol is a natural substance that may help improve insulin sensitivity and support ovarian function.

What it treats

  • polycystic ovary syndrome (PCOS)
  • insulin resistance
  • ovarian health

How it works

Myo-inositol helps in the regulation of insulin and may promote better ovarian function, which can be beneficial for women with certain reproductive health issues.

Who it's for

This supplement is often used by women, particularly those dealing with polycystic ovary syndrome or insulin-related conditions.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: myoinositol

BNF-referenced

Myo-inositol is a naturally occurring carbohydrate and a form of inositol, which is a six-carbon cyclic sugar alcohol. It plays a crucial role in cellular processes, particularly in the formation of phosphoinositides that are involved in cell signaling pathways. Myo-inositol is commonly used as a dietary supplement and has garnered attention for its potential benefits in various health conditions, including polycystic ovary syndrome (PCOS) and metabolic disorders.

Indications

  • Polycystic ovary syndrome (PCOS)
  • Insulin resistance
  • Metabolic syndrome
  • Mood disorders
  • Neurodegenerative diseases

Dosage

Children: Dosage for paediatric patients is not established; refer to BNF for Children for specific guidance.

Adults: The typical adult dose of myo-inositol is 2 to 4 grams daily, usually divided into two doses.

Mechanism of action

Myo-inositol functions primarily as a precursor in the biosynthesis of inositol phosphates, which are critical for cell signaling. It contributes to the synthesis of 1D-myo-inositol hexakisphosphate and other inositol phosphates, facilitating the regulation of cellular functions such as insulin signaling and lipid metabolism. Myo-inositol also plays a role in the modulation of neurotransmitter signaling, particularly in the central nervous system.

Pharmacodynamics

Myo-inositol has been shown to influence insulin sensitivity and may help in restoring ovarian function in women with PCOS. It acts as a second messenger in various hormonal signaling pathways, particularly those involving insulin and follicle-stimulating hormone (FSH). The drug's action can lead to improved ovarian response and metabolic profiles in affected individuals.

Pharmacokinetics

Myo-inositol is well-absorbed when administered orally, with a bioavailability that may vary based on the formulation. It is distributed throughout the body and has a half-life that supports multiple dosing regimens. Myo-inositol is eliminated primarily through renal excretion, and its metabolism is closely linked to the pathways of inositol phosphate metabolism.

Pregnancy

The safety of myoinositol during pregnancy has not been established. Consultation with a healthcare professional is advised.

Breast-feeding

Myoinositol is generally considered safe during breastfeeding, but it is recommended to consult a healthcare provider for personalized advice.

Storage

Store at room temperature, away from moisture and direct sunlight. Keep out of reach of children.

Formulations

  • Powder
  • Tablet
  • Capsule

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.